April 26th 2024
During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Rationale for In-Depth Analysis of BTK Inhibitor Tolerability in CLL
April 29th 2022John F. Seymour, MBBS, PhD, discusses the rationale for a post-hoc analysis of the phase 3 ELEVATE-RR trial comparing acalabrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.
Watch
FDA Approval Application for U2 Regimen in CLL and SLL Voluntarily Withdrawn
April 18th 2022With an increasing imbalance in overall survival, the FDA approval application for the combination of ublituximab and umbralisib for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma has been withdrawn.
Read More
New Methods May Make CAR Therapies More Effective for Patients With CLL
March 30th 2022Research results suggest that CAR T-cell therapy can overcome T cell defects caused by chronic lymphocytic leukemia, with remissions possibly lasting more than a decade for patients with significant disease burden when treated with CD4+ CAR T cells
Read More
Venetoclax Consolidation Is Well Tolerated in Patients with Previously Untreated CLL
March 29th 2022Venetoclax consolidation after 12-cycles of treatment increases the duration of known toxicities and does not prevent the loss of minimal residual disease response and subsequent risk of disease relapse in patients with previously untreated chronic lymphocytic leukemia, a study shows.
Read More
ARI-0001 CAR T-Cell Treatment Shows Promise in R/R CLL, Small Study Shows
March 21st 2022Successful CAR T-cell production was achieved in all 11 patients who underwent apheresis and cell production but were still alive at the time of infusion, according to result presented during the BMT- EHA 4th European CAR T-Cell Meeting.
Read More
Awan Compares BTK Inhibition and Other Treatments for a Patient With CLL
February 18th 2022During a Targeted Oncology case-based roundtable event, Farrukh Awan, MD, discussed the data supporting treatments for chronic lymphocytic leukemia including venetoclax and obinutuzumab, acalabrutinib, and ibrutinib.
Read More
Adding Ibrutinib Improves the Efficacy of Liso-Cel in R/R CLL
January 28th 2022Chimeric antigen receptor T-cell therapies have demonstrated potential in chronic lymphocytic leukemia. However, T-cell dysfunction that is inherent to the disease, including reduced proliferative and cytotoxic capacities, limits the efficacy of this approach, according to an expert.
Read More
Roundtable Discussion: Pagel Walks Through Treatment Choices in Chronic Lymphocytic Leukemia
January 16th 2022During a Targeted Oncology live event, John M. Pagel, MD, PhD, and participants discussed their experiences with BTK inhibitors such as acalabrutinib and ibrutinib in terms of efficacy and tolerability as well as other treatment options in patients with chronic lymphocytic leukemia.
Read More
Zanubrutinib/Venetoclax Shows Efficacy in High-Risk CLL Subgroup
January 5th 2022Jennifer R. Brown, MD, PhD, discusses the interim results of the SEQUOIA trial , which investigated the combination of zanubrutinib and venetoclax for patients with treatment-naïve chronic lymphocytic leukemia or small lymphocytic lymphoma.
Watch
Part 2: Supporting Data for Ibrutinib-Based Regimens in Frontline CLL
December 22nd 2021During a live virtual event, Jose Sandoval Sus, MD, discussed with participating physicians frontline treatment options for patients with chronic lymphocytic leukemia, with questions by Targeted Oncology.
Read More